Investigational drug · Phase 3
Remternetug
Also called: LY3372993
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer's Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "Remternetug"
First trial start
2024
Oct 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Remternetug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer's Disease
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Remternetug" as an intervention, largest first.
- A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05463731 · 1,667 participants · Start Aug 1, 2022 · Primary completion Apr 24, 2024
Drug: Remternetug (IV); Remternetug (SC) and 1 more · For: Alzheimer's Disease
Sites: Chandler, Arizona; Canoga Park, California; Carlsbad, California · 76 sites in all
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)Pivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06653153 · 1,400 participants (planned) · Start Oct 24, 2024 · Primary completion Apr 2029
Drug: Remternetug; Placebo · For: Alzheimer's Disease
Sites: Birmingham, Alabama; Chandler, Arizona; Mesa, Arizona · 262 sites in all
- A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPivotal-lookingRecruiting
Washington University School of MedicineAcademic, hospital or other
NCT05552157 · 280 participants (planned) · Start Nov 22, 2024 · Primary completion Mar 30, 2034
Drug: Remternetug (SC); Matching Placebo (Remternetug) · For: Alzheimers Disease; Dementia; Alzheimers Disease, Familial
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 37 sites in all
- A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPivotal-lookingRecruiting
Washington University School of MedicineAcademic, hospital or other
NCT06647498 · 280 participants (planned) · Start Nov 22, 2024 · Primary completion Mar 2034
Drug: Remternetug; Matching Placebo (Remternetug) · For: Alzheimers Disease; Dementia; Alzheimers Disease, Familial
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 36 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07056309 · 72 participants · Start Jun 24, 2025 · Primary completion Dec 15, 2025
Drug: Remternetug (Test); Remternetug (Reference) · For: Healthy
Sites: Daytona Beach, Florida; Springfield, Missouri; Dallas, Texas
Eli Lilly and CompanyEli Lilly (LLY)
NCT07346495 · 24 participants · Start Jan 31, 2026 · Primary completion Aug 4, 2026
Drug: LY3372993; Placebo · For: Healthy
Sites: Beijing, China; Xuhui District, China
Newest research
PubMed records naming it or its code names, newest first.
- Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease.
Lozupone M, Dibello V, Sardone R, et al. · Expert Opin Emerg Drugs 2026
- Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Nonino F, Minozzi S, Sambati L, et al. · Cochrane Database Syst Rev 2026
- From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials.
Verma M, Singh NK · Metab Brain Dis 2026
- Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species.
Siebrand CJ, Bergo NJ, Lee S, et al. · J Transl Med 2025
- Successes and failures: the latest advances in the clinical development of amyloid-β-targeting monoclonal antibodies for treating Alzheimer's disease.
Panza F, Dibello V, Sardone R, et al. · Expert Opin Biol Ther 2025
- Chimeric Antigen Receptors Discriminate Between Tau and Distinct Amyloid-Beta Species.
Siebrand CJ, Bergo NJ, Lee S, et al. · bioRxiv 2025
Also in development for Alzheimer's Disease
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- TrontinemabRO7126209, RG6102Phase 34 trials
Roche (Genentech) · Alzheimers Disease, Alzheimer's Disease
- [18F]-APN-1607Phase 32 trials
JYAMS PET Research & Development Limited · Alzheimer's Disease, Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
- RO7568282Phase 22 trials
Roche (Genentech) · Parkinson's Disease, Alzheimer's Disease
- VHB937Phase 22 trials
Novartis · Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease
- ABBV-1758Phase 21 trial
AbbVie · Alzheimer's Disease
- E2814Phase 21 trial
Eisai · Alzheimer's Disease
- GSK4527226Phase 21 trial
GSK · Alzheimer's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.